{"id":3928,"date":"2019-01-15T11:41:32","date_gmt":"2019-01-15T06:11:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3928"},"modified":"2021-07-24T12:57:11","modified_gmt":"2021-07-24T07:27:11","slug":"notizia-86","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-86","title":{"rendered":"Notizia"},"content":{"rendered":"\n

Abbott\u2019s pea-sized implant for\ncongenital heart defects gets FDA approval <\/strong><\/p>\n\n\n\n

FDA <\/strong>approved Abbott <\/strong>for its Amplatzer Piccolo Occluder<\/strong>, the implant designed for premature babies<\/strong>. The device is used to treat patent ductus arteriosus (PDA)<\/strong>, a life-threatening opening in the hearts of premature newborns and is a minimally invasive procedure. PDA <\/strong>is an opening between two blood vessels leading from the heart <\/a>that fails to close during normal development. The open channel is for the flow of oxygen-rich blood from the mother before birth. When the pathway fails to close, the increased blood flow to the lungs can make it difficult for premature babies to breathe normally.<\/p>\n\n\n\n

Verona flunks after COPD drug\nmisses phase 2 endpoint<\/strong><\/p>\n\n\n\n

A phase 2<\/strong> trial of ensifentrine of Verona Pharma<\/strong> has\u00a0missed\u00a0its primary endpoint. Verona went into the readout with broadly positive data from another phase 2 in chronic obstructive pulmonary disease (COPD). But, while the earlier trial linked ensifentrine, earlier known as RPL554<\/strong>, to significant improvements in peak forced expiratory volume in one second (FEV1). It was found that it is statistically no better than placebo.<\/p>\n\n\n\n

Swiss team halts breast cancer\nmetastasis by bamboozling cells into becoming fat<\/strong><\/p>\n\n\n\n

The scientists at the University of Basel<\/strong> led to a combination of two FDA<\/strong>-approved drugs, in mice, that transformed breast cancer<\/a> cells into fat cells, and prohibited the tumors from developing. The combo treatment consisted of diabetes drug Avandia (rosiglitazone) of GlaxoSmithKline<\/strong> and cancer treatment Mekinist (trametinib) of Novartis<\/strong>. The Swiss scientists<\/strong>\u2019 experiment was their ability to exploit a developmental phase during which cancer cells are willing to turn into many different types of cells. When cancer cells enter that stage, known as an epithelial-mesenchymal transition<\/strong>, they become more like stem <\/a>cells, but they also promote metastasis as well.<\/p>\n\n\n\n

CellMax Life blood test study\ndetects precancer colorectal polyps with 90% accuracy<\/strong><\/p>\n\n\n\n

A study by CellMax Life <\/strong>found that the company’s blood-based test was able to identify the small, precancerous colon polyps <\/strong>known as adenomas <\/strong>with 90% accuracy. By counting precancer and cancer cells in the bloodstream using its CMx platform, CellMax Life\u2019s FirstSightCRC<\/strong> test also found that increase in cell counts is related with increase in disease severity. The early removal of adenoma polyps from the colon can reduce the mortality rate of colorectal cancer<\/a> by 53%<\/strong>, according to the Sunnyvale, California-based company,<\/strong> which plans to present the study\u2019s findings at the ASCO Gastrointestinal Cancer Symposium<\/strong> in San Francisco. \u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"

Abbott\u2019s pea-sized implant for congenital heart defects gets FDA approval FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus (PDA), a life-threatening opening in the hearts of premature newborns and is a minimally invasive procedure. PDA is an opening between two […]<\/p>\n","protected":false},"author":1,"featured_media":3649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2421,2420,2418,2417,2419],"industry":[17226,17225],"therapeutic_areas":[17235,17228,17433,17243],"class_list":["post-3928","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-asco-gastrointestinal-cancer-symposium","tag-california-based-company","tag-cellmax-lifes-firstsightcrc","tag-cmx-platform","tag-sunnyvale","industry-medical-devices","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-pediatrics","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"\nNotizia 15\/01.2019 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-86\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 15\/01.2019 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-86\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-15T06:11:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"752\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 15\/01.2019 - DelveInsight Business Research LLP","description":"FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-86","og_locale":"en_US","og_type":"article","og_title":"Notizia 15\/01.2019 - DelveInsight Business Research LLP","og_description":"FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus..","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-86","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-15T06:11:32+00:00","article_modified_time":"2021-07-24T07:27:11+00:00","og_image":[{"width":752,"height":501,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-86","url":"https:\/\/www.delveinsight.com\/blog\/notizia-86","name":"Notizia 15\/01.2019 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-86#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-86#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","datePublished":"2019-01-15T06:11:32+00:00","dateModified":"2021-07-24T07:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA approved Abbott for its Amplatzer Piccolo Occluder, the implant designed for premature babies. The device is used to treat patent ductus arteriosus..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-86"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-86#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501.jpg","width":752,"height":501,"caption":"patent ductus arteriosus"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/11\/09020522\/big-pharma-ireland-2-752x501-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ASCO Gastrointestinal Cancer Symposium<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">California-based company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CellMax Life\u2019s FirstSightCRC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CMx platform<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sunnyvale<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">ASCO Gastrointestinal Cancer Symposium<\/span>","<span class=\"advgb-post-tax-term\">California-based company<\/span>","<span class=\"advgb-post-tax-term\">CellMax Life\u2019s FirstSightCRC<\/span>","<span class=\"advgb-post-tax-term\">CMx platform<\/span>","<span class=\"advgb-post-tax-term\">Sunnyvale<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 15, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 15, 2019 11:41 am","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"patent ductus arteriosus","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3928"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3928\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3649"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3928"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3928"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3928"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3928"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}